Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 14/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649859 | 0.79 | HPGD (0.47) | HPGDKMT2ASMN1; SMN2KDRMAPK1 | |
| SCHEMBL7059325 | 0.78 | HPGD (0.41) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2650204 | 0.77 | HPGD (0.39) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2652084 | 0.77 | ALDH1A1 (0.44) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2649465 | 0.75 | HPGD (0.39) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2652320 | 0.74 | KMT2A (0.45) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2652583 | 0.74 | ALDH1A1 (0.49) | KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2650199 | 0.74 | HPGD (0.38) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2649181 | 0.73 | HPGD (0.38) | HPGDKMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7819821 | 0.72 | KDR (0.49) | HPGDALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | HPGD 1452/4885KMT2A 1116/4885ALDH1A1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.